Abivax has raised the efficacy bar in ulcerative colitis, linking obefazimod to a 40%, placebo-adjusted jump in clinical remission rates in a phase 3 trial. But the share price of the biotech, a reported takeover target for several Big Pharmas, collapsed after several patients on the high dose developed cancers.